Merck & Co.
Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases.
Pfizer Canada strives to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines. Our diverse portfolio offers a broad range of benefits and solutions to meet the needs of Canadians.
Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
The Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is approved for people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months has not yet been established.
KIRKLAND, QC, April 23, 2021 — Pfizer Canada today announced it has reached an agreement with the Government of Canada to supply up to 125 million doses of the Pfizer-BioNTech COVID-19 vaccine in 2022 and 2023, with options to supply up to 60 million additional doses in 2024.
Dec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted FDA approval. Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose. More than 1.2 billion Pfizer-BioNTech doses have been delivered to more than 120 countries or territories around the world since December 2020.
5 days ago · Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study ( NCT04370054 ) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A.
